ACADIA Pharmaceuticals, Inc. (ACAD)
17.11
-0.48
(-2.73%)
USD |
NASDAQ |
Nov 20, 16:00
17.10
-0.01
(-0.06%)
After-Hours: 20:00
ACADIA Pharmaceuticals Research and Development Expense (TTM) : 319.46M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 319.46M |
| June 30, 2026 | 331.01M |
| March 31, 2026 | 327.40M |
| December 31, 2025 | 328.80M |
| September 30, 2025 | 344.78M |
| June 30, 2025 | 323.55M |
| March 31, 2025 | 321.84M |
| December 31, 2024 | 303.25M |
| September 30, 2024 | 269.26M |
| June 30, 2024 | 359.62M |
| March 31, 2024 | 342.15M |
| December 31, 2023 | 351.62M |
| September 30, 2023 | 360.62M |
| June 30, 2023 | 284.99M |
| March 31, 2023 | 301.86M |
| December 31, 2022 | 361.58M |
| September 30, 2022 | 352.92M |
| June 30, 2022 | 330.15M |
| March 31, 2022 | 311.44M |
| December 31, 2021 | 239.56M |
| September 30, 2021 | 181.79M |
| June 30, 2021 | 190.51M |
| March 31, 2021 | 197.87M |
| December 31, 2020 | 213.53M |
| September 30, 2020 | 261.73M |
| Date | Value |
|---|---|
| June 30, 2020 | 257.07M |
| March 31, 2020 | 260.10M |
| December 31, 2019 | 240.38M |
| September 30, 2019 | 231.05M |
| June 30, 2019 | 221.54M |
| March 31, 2019 | 200.81M |
| December 31, 2018 | 187.16M |
| September 30, 2018 | 182.16M |
| June 30, 2018 | 165.47M |
| March 31, 2018 | 153.06M |
| December 31, 2017 | 149.19M |
| September 30, 2017 | 136.23M |
| June 30, 2017 | 125.62M |
| March 31, 2017 | 111.92M |
| December 31, 2016 | 99.28M |
| September 30, 2016 | 89.53M |
| June 30, 2016 | 82.45M |
| March 31, 2016 | 80.35M |
| December 31, 2015 | 73.87M |
| September 30, 2015 | 71.58M |
| June 30, 2015 | 69.81M |
| March 31, 2015 | 65.23M |
| December 31, 2014 | 60.60M |
| September 30, 2014 | 50.34M |
| June 30, 2014 | 40.65M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 929.60M |
| Ionis Pharmaceuticals, Inc. | 921.08M |
| Arcturus Therapeutics Holdings, Inc. | 75.82M |
| ADMA Biologics, Inc. | 14.48M |
| Viking Therapeutics, Inc. | 586.17M |